The United States Food and Drug Administration (USFDA) has completed an inspection at Gland Pharma’s API Facility at JNPC, Visakhapatnam from May 20, 2024 to May 24, 2024. The inspection has been completed with Zero 483 observations.
Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.